ArticleInternational journal of medical sciences2026
TNFSF13 Drives Atherosclerosis Progression by Targeting Macrophage Senescence.
Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerosis (AS), a complex age-related disease characterized by arterial lipid plaque formation, remains poorly understood at the molecular level. Senescent cells, particularly macrophages, drive plaque progression, but key senescence-inducing genes and their mechanisms are unclear. Method: Senescence-related DEGs (SR-DEGs) were identified by intersecting differentially expressed genes (DEGs) from GSE28829 with senescence-related genes (SRGs) in CellAge genes. Machine learning algorithms prioritized hub genes, whose expression and diagnostic performance were subsequently visualized with box plots and receiver operating characteristic (ROC) curves in the training dataset GSE28829, and validation sets GSE163154 and GSE100927. Immune infiltration analysis compared early and advanced plaques. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) mapped hub gene expression across cell types and plaque regions. TNFSF13 was further validated in clinical atherosclerosis samples using Quantitative Real-time PCR (RT-qPCR), immunohistochemistry (IHC) and multiplex Immunohistochemistry (mIHC). Results: Advanced plaques exhibited 74 SR-DEGs compared to early plaques. Machine learning identified six senescence-related hub genes. ScRNA-seq revealed macrophage enrichment of all six hub genes, aligning with immune infiltration results. Bayesian deconvolution confirmed macrophage compositional shifts. Cell-cell communication analysis implicated TNFSF13-associated pathways. Spatial transcriptomics localized TNFSF13 upregulation specifically to the plaque core region, rich in SPP1+ macrophages and foam macrophages. Critically, TNFSF13 upregulation was robustly validated in human coronary artery tissues. Conclusion: This study identifies TNFSF13 as a master regulator of macrophage senescence driving atherosclerosis progression. By leveraging multi-omics and machine learning, we pinpoint the spatial and cellular context of TNFSF13 within plaques and validate its clinical relevance. TNFSF13 represents a promising therapeutic target to disrupt senescence-mediated plaque advancement in AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.